Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SML009
MIFTS: 36

Small Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Small Intestine Adenocarcinoma

About this section

MalaCards integrated aliases for Small Intestine Adenocarcinoma:

Name: Small Intestine Adenocarcinoma 12 15
Adenocarcinoma of the Small Instestine 53 59
Adenocarcinoma of the Small Bowel 53 59
Small Intestinal Adenocarcinoma 12 53
Adenocarcinoma of Small Instestine 53
Adenocarcinoma of Small Intestine 12
Adenocarcinoma of Small Bowel 53
Small Bowel Adenocarcinoma 53

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:4906
NCIt 50 C7888
Orphanet 59 ORPHA104075
ICD10 via Orphanet 34 D01.4
UMLS via Orphanet 74 C0278803
UMLS 73 C0278803
Sources

Summaries for Small Intestine Adenocarcinoma

About this section
NIH Rare Diseases : 53 Small intestine adenocarcinoma is one type of small bowel cancer, usually occurring in the duodenum or jejunum, that begins in the gland cells. The small intestine is part of the body�??s digestive system, which also includes the esophagus, stomach, and large intestine. The exact cause is still unknown, but it may be due to DNA changes in the small intestine adenocarcinoma cells. The symptoms of small bowel tumors are often vague. The most common symptoms are pain in the belly (which may be the first symptom), weight loss, weakness, fatigue and low red blood cell counts (anemia). The treatment and prognosis for small intestine cancer depends on its stage (tumor size and site) and the presence of metastases. For early stage cancer, surgery may be all that is needed. For more advanced cancer chemotherapy or radiation therapy may be required. Please visit the National Cancer Institute website for additional information:Small Intestine Cancer Treatment (PDQ®)�??Patient Version

MalaCards based summary : Small Intestine Adenocarcinoma, also known as adenocarcinoma of the small instestine, is related to mucinous adenocarcinoma and colorectal adenocarcinoma. An important gene associated with Small Intestine Adenocarcinoma is USP10 (Ubiquitin Specific Peptidase 10), and among its related pathways/superpathways are Diseases of glycosylation and Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC). The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include small intestine, endothelial and pancreas.

Disease Ontology : 12 A small intestine carcinoma that derives from epithelial cells of glandular origin.

Sources

Related Diseases for Small Intestine Adenocarcinoma

About this section

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Small Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 mucinous adenocarcinoma 29.7 MLH1 MUC2
2 colorectal adenocarcinoma 29.5 MLH1 MUC2
3 lynch syndrome 29.5 MLH1 MUC2
4 adenocarcinoma 10.6
5 celiac disease 1 10.1
6 mucinous intrahepatic cholangiocarcinoma 10.0 MUC2 MUC6
7 tumor of exocrine pancreas 10.0 MUC2 MUC6
8 pancreatic intraductal papillary-mucinous neoplasm 10.0 MUC2 MUC6
9 chronic ethmoiditis 10.0 MUC2 MUC6
10 duodenum adenocarcinoma 10.0 MUC2 MUC6
11 bile duct cystadenocarcinoma 10.0 MUC2 MUC6
12 appendix disease 10.0 MUC2 MUC6
13 mucinous tubular and spindle renal cell carcinoma 10.0 MUC2 MUC6
14 biliary papillomatosis 10.0 MUC2 MUC6
15 ethmoid sinusitis 10.0 MUC2 MUC6
16 superior mesenteric artery syndrome 10.0 MUC2 MUC6
17 duodenal disease 10.0 MUC2 MUC6
18 ovarian mucinous neoplasm 10.0 MUC2 MUC6
19 appendix cancer 10.0 MUC2 MUC6
20 cystic teratoma 10.0 MUC2 MUC6
21 duodenum cancer 10.0 MUC2 MUC6
22 pseudomyxoma peritonei 10.0 MUC2 MUC6
23 gastric tubular adenocarcinoma 10.0 MUC2 MUC6
24 tn polyagglutination syndrome 10.0 MUC2 MUC6
25 signet ring cell adenocarcinoma 10.0 MUC2 MUC6
26 ampulla of vater cancer 10.0 MUC2 MUC6
27 pancreatic ductal carcinoma 10.0 MUC2 MUC6
28 bronchiolo-alveolar adenocarcinoma 10.0 MUC2 MUC6
29 deficiency anemia 10.0
30 iron deficiency anemia 10.0
31 iron metabolism disease 10.0
32 epstein-barr virus-associated gastric carcinoma 10.0 MUC2 MUC6
33 cystadenoma 10.0 MUC2 MUC6
34 colorectal cancer 1 10.0 MUC2 MUC6
35 cholecystitis 10.0 MUC2 MUC6
36 crohn's disease 10.0
37 microinvasive gastric cancer 9.9 MLH1 MUC2
38 pancreas adenocarcinoma 9.9 MUC2 MUC6
39 polyposis syndrome, hereditary mixed, 1 9.9 MLH1 MUC6
40 intestinal benign neoplasm 9.9 MLH1 MUC2
41 adenomyoma 9.9 MLH1 MUC6
42 barrett esophagus 9.9 MUC2 MUC6
43 intestinal disease 9.9 MLH1 MUC2
44 gastritis 9.9
45 lymphocytic gastritis 9.9
46 gastrointestinal system cancer 9.9 MLH1 MUC2
47 gastrointestinal system disease 9.9 MLH1 MUC2
48 colorectal cancer 9.8
49 intussusception 9.8
50 aging 9.8

Graphical network of the top 20 diseases related to Small Intestine Adenocarcinoma:



Diseases related to Small Intestine Adenocarcinoma
Sources

Symptoms & Phenotypes for Small Intestine Adenocarcinoma

About this section
Sources

Drugs & Therapeutics for Small Intestine Adenocarcinoma

About this section

Drugs for Small Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
8
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
9 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
10 Central Nervous System Depressants Phase 3
11 Adjuvants, Anesthesia Phase 3
12 Anesthetics, Intravenous Phase 3
13 Analgesics, Opioid Phase 3
14 Peripheral Nervous System Agents Phase 3
15 Anesthetics, General Phase 3
16 Analgesics Phase 3
17 Narcotics Phase 3
18 Anesthetics Phase 3
19 BB 1101 Phase 3
20 Antipruritics Phase 3
21 Serotonin Agents Phase 3
22 Anti-Inflammatory Agents Phase 3
23 Hormone Antagonists Phase 3
24 Antipsychotic Agents Phase 3
25 Dermatologic Agents Phase 3,Not Applicable
26 Gastrointestinal Agents Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
28 glucocorticoids Phase 3
29 Serotonin Antagonists Phase 3
30 Tranquilizing Agents Phase 3
31 Hormones Phase 3
32 Antineoplastic Agents, Hormonal Phase 3,Phase 2
33 Antiemetics Phase 3
34 Anti-Anxiety Agents Phase 3
35
protease inhibitors Phase 3
36 Autonomic Agents Phase 3
37 Psychotropic Drugs Phase 3
38 HIV Protease Inhibitors Phase 3
39 Neurotransmitter Agents Phase 3
40
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
41
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
42
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
43
Irinotecan Approved, Investigational Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
44
Bevacizumab Approved, Investigational Phase 2 216974-75-3
45
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
46
Melphalan Approved Phase 2 148-82-3 4053 460612
47
Hydroxyurea Approved Phase 2 127-07-1 3657
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
50
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma Not yet recruiting NCT02502370 Phase 3 observation alone;LV5FU2;FOLFOX
6 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
7 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
8 Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer Completed NCT00433550 Phase 2 capecitabine;irinotecan hydrochloride;oxaliplatin
9 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Completed NCT01202409 Phase 2 Panitumumab
10 Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
11 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
12 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
13 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
14 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
15 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery Completed NCT00004895 Phase 2 octreotide acetate
16 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
17 Cobimetinib and Atezolizumab in Advanced Rare Tumors Recruiting NCT03108131 Phase 2 Cobimetinib;Atezolizumab
18 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
19 Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting NCT02949219 Phase 2
20 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting NCT02034110 Phase 2 Dabrafenib;Trametinib
21 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
22 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
23 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
24 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
25 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
26 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
27 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
28 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
29 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
30 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
31 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
32 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
33 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
34 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Completed NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
35 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
36 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
37 Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer Completed NCT00019773 Phase 1 capecitabine;oxaliplatin
38 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1 capecitabine;cisplatin
39 Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Recruiting NCT03000179 Phase 1 Avelumab
40 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting NCT03095781 Phase 1 XL888
41 Enteroscopy for Early Diagnosis of Tumors in Celiac Disease Unknown status NCT02325232 Not Applicable
42 Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder Completed NCT00489515
43 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
44 Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease Recruiting NCT03095573 Not Applicable
45 Phenotyping of Small Bowel Adenocarcinoma Active, not recruiting NCT02976090
46 Prospective Collection of PillCam SB3 Videos and Raw Data Files With Abnormal Findings for Future Developments (SODA) Not yet recruiting NCT03771508
47 EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer Terminated NCT00087191 Not Applicable EF5;motexafin lutetium

Search NIH Clinical Center for Small Intestine Adenocarcinoma

Sources

Genetic Tests for Small Intestine Adenocarcinoma

About this section
Sources

Anatomical Context for Small Intestine Adenocarcinoma

About this section

MalaCards organs/tissues related to Small Intestine Adenocarcinoma:

41
Small Intestine, Endothelial, Pancreas, Appendix
Sources

Publications for Small Intestine Adenocarcinoma

About this section

Articles related to Small Intestine Adenocarcinoma:

# Title Authors Year
1
Lifestyle factors and small intestine adenocarcinoma risk: A systematic review and meta-analysis. ( 25736860 )
2015
2
S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. ( 24062356 )
2013
3
Small intestine adenocarcinoma in conjunction with multiple adenomas causing acute colic in a horse. ( 18182527 )
2008
4
Adjuvant chemotherapy for small intestine adenocarcinoma. ( 17636789 )
2007
5
Mucinous adenocarcinoma of the small bowel with peritoneal seeding. ( 11869008 )
2002
6
[Crohn's disease and small intestine adenocarcinoma]. ( 11534361 )
2001
7
Enteroscopic identification of an adenocarcinoma of the small bowel in a patient with previously unrecognized hereditary nonpolyposis colorectal cancer syndrome. ( 10406269 )
1999
8
Adenocarcinoma of the small bowel, coeliac disease, and lymphocytic gastritis. ( 10193339 )
1998
9
Electron microscopic study of adenocarcinoma of the small bowel associated with Crohn's disease. ( 6840256 )
1983
Sources

Variations for Small Intestine Adenocarcinoma

About this section

Cosmic variations for Small Intestine Adenocarcinoma:

9 (show top 50) (show all 21683)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6971229 ZRSR2 small intestine,duodenum,carcinoma,adenocarcinoma c.611G>A p.S204N 23:15815730-15815730 24
2 COSM6973250 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.1691C>T p.A564V 16:72958455-72958455 24
3 COSM6845179 ZFHX3 small intestine,jejunum,carcinoma,adenocarcinoma c.8576C>T p.T2859M 16:72794106-72794106 24
4 COSM6913839 WT1 small intestine,duodenum,carcinoma,adenocarcinoma c.538G>T p.D180Y 11:32428524-32428524 24
5 COSM1130534 U2AF1 small intestine,duodenum,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 24
6 COSM6968949 TSC2 small intestine,duodenum,carcinoma,adenocarcinoma c.710C>T p.P237L 16:2056705-2056705 24
7 COSM6917759 TSC2 small intestine,jejunum,carcinoma,adenocarcinoma c.3551C>A p.A1184E 16:2080318-2080318 24
8 COSM11090 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.541C>T p.R181C 17:7675071-7675071 24
9 COSM44218 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.536A>C p.H179P 17:7675076-7675076 24
10 COSM43970 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.380C>A p.S127Y 17:7675232-7675232 24
11 COSM10738 TP53 small intestine,duodenum,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 24
12 COSM10788 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.764T>G p.I255S 17:7674199-7674199 24
13 COSM5731186 TP53 small intestine,jejunum,carcinoma,adenocarcinoma c.1052A>G p.K351R 17:7670657-7670657 24
14 COSM4116810 TGFBR2 small intestine,jejunum,carcinoma,adenocarcinoma c.1277C>T p.A426V 3:30674127-30674127 24
15 COSM6961805 TGFBR1 small intestine,duodenum,carcinoma,adenocarcinoma c.1124C>A p.T375K 9:99144882-99144882 24
16 COSM6968905 TET2 small intestine,duodenum,carcinoma,adenocarcinoma c.1124A>G p.E375G 4:105235066-105235066 24
17 COSM6973233 TENT5C small intestine,jejunum,carcinoma,adenocarcinoma c.839A>G p.D280G 1:117623707-117623707 24
18 COSM6971222 SUZ12 small intestine,duodenum,carcinoma,adenocarcinoma c.1058C>A p.P353H 17:31988354-31988354 24
19 COSM25847 STK11 small intestine,duodenum,carcinoma,adenocarcinoma c.580G>A p.D194N 19:1220488-1220488 24
20 COSM6973254 STK11 small intestine,jejunum,carcinoma,adenocarcinoma c.719C>T p.S240L 19:1220702-1220702 24
21 COSM6968955 STAT3 small intestine,duodenum,carcinoma,adenocarcinoma c.635A>G p.Q212R 17:42337773-42337773 24
22 COSM6946712 STAG2 small intestine,duodenum,carcinoma,adenocarcinoma c.3018T>G p.F1006L 23:124083514-124083514 24
23 COSM1227526 SRC small intestine,duodenum,carcinoma,adenocarcinoma c.1460C>T p.P487L 20:37403228-37403228 24
24 COSM6968895 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.617G>A p.R206H 1:15876414-15876414 24
25 COSM2087949 SPEN small intestine,duodenum,carcinoma,adenocarcinoma c.4586G>A p.R1529H 1:15930826-15930826 24
26 COSM6959363 SOX9 small intestine,duodenum,carcinoma,adenocarcinoma c.242T>C p.L81P 17:72121633-72121633 24
27 COSM6968916 SMO small intestine,duodenum,carcinoma,adenocarcinoma c.1571C>T p.A524V 7:129210467-129210467 24
28 COSM6971224 SMARCA4 small intestine,duodenum,carcinoma,adenocarcinoma c.2647G>T p.G883C 19:11021755-11021755 24
29 COSM14123 SMAD4 small intestine,jejunum,carcinoma,adenocarcinoma c.1087T>A p.C363S 18:51065554-51065554 24
30 COSM988907 SMAD4 small intestine,duodenum,carcinoma,adenocarcinoma c.1612G>A p.E538K 18:51078420-51078420 24
31 COSM6972746 SMAD3 small intestine,duodenum,carcinoma,adenocarcinoma c.1027T>G p.F343V 15:67187382-67187382 24
32 COSM6968957 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.938T>C p.L313S 18:47848534-47848534 24
33 COSM6959364 SMAD2 small intestine,duodenum,carcinoma,adenocarcinoma c.1298G>A p.S433N 18:47841933-47841933 24
34 COSM6968893 SH2B3 small intestine,duodenum,carcinoma,adenocarcinoma c.616G>A p.A206T 12:111418761-111418761 24
35 COSM6973235 SF3B1 small intestine,jejunum,carcinoma,adenocarcinoma c.1226C>A p.P409Q 2:197408011-197408011 24
36 COSM6968956 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.2875T>C p.F959L 17:80925436-80925436 24
37 COSM2804280 RPTOR small intestine,duodenum,carcinoma,adenocarcinoma c.3104C>T p.T1035M 17:80945745-80945745 24
38 COSM5839152 RPS6KA4 small intestine,jejunum,carcinoma,adenocarcinoma c.806C>T p.A269V 11:64361902-64361902 24
39 COSM4638831 RPS6KA4 small intestine,duodenum,carcinoma,adenocarcinoma c.1355G>A p.R452H 11:64368724-64368724 24
40 COSM6961801 ROS1 small intestine,duodenum,carcinoma,adenocarcinoma c.1289G>A p.G430D 6:117389820-117389820 24
41 COSM6917742 REL small intestine,duodenum,carcinoma,adenocarcinoma c.323G>A p.R108Q 2:60901012-60901012 24
42 COSM6960242 RECQL4 small intestine,duodenum,carcinoma,adenocarcinoma c.1649C>T p.A550V 8:144514497-144514497 24
43 COSM181063 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.770C>T p.S257L 3:12604200-12604200 24
44 COSM1536534 RAF1 small intestine,jejunum,carcinoma,adenocarcinoma c.776C>T p.S259F 3:12604194-12604194 24
45 COSM6968897 RAD54L small intestine,duodenum,carcinoma,adenocarcinoma c.1181G>A p.R394Q 1:46272477-46272477 24
46 COSM6954429 RAD50 small intestine,duodenum,carcinoma,adenocarcinoma c.3419G>A p.R1140H 5:132642261-132642261 24
47 COSM6968919 RAD21 small intestine,duodenum,carcinoma,adenocarcinoma c.1642G>A p.D548N 8:116849008-116849008 24
48 COSM6968969 PTPRT small intestine,duodenum,carcinoma,adenocarcinoma c.4300A>G p.T1434A 20:42081920-42081920 24
49 COSM6973262 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.341G>T p.G114V 19:5273480-5273480 24
50 COSM6973259 PTPRS small intestine,jejunum,carcinoma,adenocarcinoma c.2698A>G p.T900A 19:5223094-5223094 24

Copy number variations for Small Intestine Adenocarcinoma from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13776 1 1 39600000 Copy number LCK Small bowel adenocarcinoma
2 13777 1 1 39600000 Copy number MDS2 Small bowel adenocarcinoma
3 13778 1 1 39600000 Copy number PAX7 Small bowel adenocarcinoma
4 13779 1 1 39600000 Copy number PRDM16 Small bowel adenocarcinoma
5 13780 1 1 39600000 Copy number RPL22 Small bowel adenocarcinoma
6 13781 1 1 39600000 Copy number SDHB Small bowel adenocarcinoma
7 76578 13 32900000 93800000 Copy number LCP1 Small bowel adenocarcinoma
8 76579 13 32900000 93800000 Copy number LHFP Small bowel adenocarcinoma
9 76580 13 32900000 93800000 Copy number RB1 Small bowel adenocarcinoma
10 106872 17 1 6800000 Copy number USP6 Small bowel adenocarcinoma
11 180663 4 10900000 191273063 Copy number CHIC2 Small bowel adenocarcinoma
12 180664 4 10900000 191273063 Copy number FBXW7 Small bowel adenocarcinoma
13 180665 4 10900000 191273063 Copy number FIP1L1 Small bowel adenocarcinoma
14 180666 4 10900000 191273063 Copy number IL2 Small bowel adenocarcinoma
15 180667 4 10900000 191273063 Copy number KIT Small bowel adenocarcinoma
16 180668 4 10900000 191273063 Copy number PDGFRA Small bowel adenocarcinoma
17 180669 4 10900000 191273063 Copy number PHOX2B Small bowel adenocarcinoma
18 180670 4 10900000 191273063 Copy number RAP1GDS1 Small bowel adenocarcinoma
19 244962 9 1 51800000 Copy number FANCG Small bowel adenocarcinoma
20 244963 9 1 51800000 Copy number JAK2 Small bowel adenocarcinoma
21 244964 9 1 51800000 Copy number MLLT3 Small bowel adenocarcinoma
22 244965 9 1 51800000 Copy number PAX5 Small bowel adenocarcinoma
Sources

Expression for Small Intestine Adenocarcinoma

About this section
Search GEO for disease gene expression data for Small Intestine Adenocarcinoma.
Sources

Pathways for Small Intestine Adenocarcinoma

About this section

Pathways related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Diseases of glycosylation 66
Show member pathways
 11.12 MUC2 MUC6
2
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) 66
Show member pathways
 10.66 MUC2 MUC6
Sources

GO Terms for Small Intestine Adenocarcinoma

About this section

Cellular components related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.62 MUC2 MUC6

Biological processes related to Small Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.16 MUC2 MUC6
2 O-glycan processing GO:0016266 8.96 MUC2 MUC6
3 maintenance of gastrointestinal epithelium GO:0030277 8.62 MUC2 MUC6
Sources

Sources for Small Intestine Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....